Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer

References

• Twelves C, Wong A, Nowacki MP, Abt M, Burris H, 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Eng J Med 2005; 352:2696-704; PMID:15987918; https://doi.org/10.1056/NEJMoa043116
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Eng J Med 2004; 350:2343-51; PMID:15175436; https://doi.org/10.1056/NEJMoa032709
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27:3109-16; PMID:19451431; https://doi.org/10.1200/JCO.2008.20.6771
   PubMed Web of Science ®Google Scholar
• Yothers G, O'Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, Wolmark N. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011; 29:3768-74; PMID:21859995; https://doi.org/10.1200/JCO.2011.36.4539
   PubMed Web of Science ®Google Scholar
• Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 2012; 307:1383-93; PMID:22474202; https://doi.org/10.1001/jama.2012.385
   PubMed Web of Science ®Google Scholar
• Shi Q, Andre T, Grothey A, Yothers G, Hamilton SR, Bot BM, Haller DG, Van Cutsem E, Twelves C, Benedetti JK, et al. Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database. J Clin Oncol 2013; 31:3656-63; PMID:23980089; https://doi.org/10.1200/JCO.2013.49.4344
   PubMed Web of Science ®Google Scholar
• de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012; 13:1225-33; PMID:23168362; https://doi.org/10.1016/S1470-2045(12)70509-0
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Lopa SH, Wolmark N. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol 2013; 31:359-64; PMID:23233715; https://doi.org/10.1200/JCO.2012.44.4711
   PubMed Web of Science ®Google Scholar
• Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15:862-73; PMID:24928083; https://doi.org/10.1016/S1470-2045(14)70227-X
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol 2015; 33:1787-96; PMID:25918287; https://doi.org/10.1200/JCO.2014.60.0213
   PubMed Web of Science ®Google Scholar
• Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology 2015; 148:88-99; PMID:25305506; https://doi.org/10.1053/j.gastro.2014.09.041
   PubMed Web of Science ®Google Scholar
• Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Eng J Med 2012; 367:1596-606; PMID:23094721; https://doi.org/10.1056/NEJMoa1207756
   PubMed Web of Science ®Google Scholar
• Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F, Allavena P, Torri V, Repici A, Santoro A, et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 2009; 10:877-84; PMID:19656725; https://doi.org/10.1016/S1470-2045(09)70186-X
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29:610-8; PMID:21245428; https://doi.org/10.1200/JCO.2010.30.5425
   PubMed Web of Science ®Google Scholar
• Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol 2014; 232:199-209; PMID:24122236; https://doi.org/10.1002/path.4287
   PubMed Web of Science ®Google Scholar
• Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010; 222:350-66; PMID:20927778; https://doi.org/10.1002/path.2774
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436-44; PMID:18650914; https://doi.org/10.1038/nature07205
   PubMed Web of Science ®Google Scholar
• Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013; 339:286-91; PMID:23329041; https://doi.org/10.1126/science.1232227
   PubMed Web of Science ®Google Scholar
• Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, Zhao YW, Wei YQ. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. Plos One 2012; 7:e50946; PMID:23284651; https://doi.org/10.1371/journal.pone.0050946
   PubMed Web of Science ®Google Scholar
• Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol 2013; 35:585-600; PMID:23657835; https://doi.org/10.1007/s00281-013-0367-7
   PubMed Web of Science ®Google Scholar
• Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 2007; 13:1472-9; PMID:17332291; https://doi.org/10.1158/1078-0432.CCR-06-2073
   PubMed Web of Science ®Google Scholar
• Zhou Q, Peng RQ, Wu XJ, Xia Q, Hou JH, Ding Y, Zhou QM, Zhang X, Pang ZZ, Wan DS, et al. The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. J Transl Med 2010; 8:13; PMID:20141634; https://doi.org/10.1186/1479-5876-8-13
   PubMed Web of Science ®Google Scholar
• Algars A, Irjala H, Vaittinen S, Huhtinen H, Sundstrom J, Salmi M, Ristamäki R, Jalkanen S. Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients. Int J Cancer 2012; 131:864-73; PMID:21952788; https://doi.org/10.1002/ijc.26457
   PubMed Web of Science ®Google Scholar
• Edin S, Wikberg ML, Dahlin AM, Rutegard J, Oberg A, Oldenborg PA, Palmqvist R. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. Plos One 2012; 7:e47045; PMID:23077543; https://doi.org/10.1371/journal.pone.0047045
   PubMed Web of Science ®Google Scholar
• de Jong D, Koster A, Hagenbeek A, Raemaekers J, Veldhuizen D, Heisterkamp S, de Boer JP, van Glabbeke M. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 2009; 94:70-7; PMID:19059937; https://doi.org/10.3324/haematol.13574
   PubMed Web of Science ®Google Scholar
• Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 2007; 13:5784-9; PMID:17908969; https://doi.org/10.1158/1078-0432.CCR-07-0778
   PubMed Web of Science ®Google Scholar
• Kridel R, Xerri L, Gelas-Dore B, Tan K, Feugier P, Vawda A, Canioni D, Farinha P, Boussetta S, Moccia AA, et al. The prognostic impact of CD163-positive macrophages in follicular lymphoma: A study from the BC cancer agency and the lymphoma study association. Clin Cancer Res 2015; 21:3428-35; PMID:25869385; https://doi.org/10.1158/1078-0432.CCR-14-3253
   PubMed Web of Science ®Google Scholar
• De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer cell 2013; 23:277-86; PMID:23518347; https://doi.org/10.1016/j.ccr.2013.02.013
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med 2015; 212:435-45; PMID:25753580; https://doi.org/10.1084/jem.20150295
   PubMed Web of Science ®Google Scholar
• Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 2017; 14(7):399-416; PMID:28117416; https://doi.org/10.1038/nrclinonc.2016.217
   PubMed Web of Science ®Google Scholar
• Mantovani A, Polentarutti N, Luini W, Peri G, Spreafico F. Role of host defense merchanisms in the antitumor activity of adriamycin and daunomycin in mice. J Natl Cancer Inst 1979; 63:61-6; PMID:286835; https://doi.org/10.1093/jnci/63.1.61
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; https://doi.org/10.1146/annurev-immunol-032712-100008
   PubMed Web of Science ®Google Scholar
• Alizadeh D, Larmonier N. Chemotherapeutic targeting of cancer-induced immunosuppressive cells. Cancer Res 2014; 74:2663-8; PMID:24778417; https://doi.org/10.1158/0008-5472.CAN-14-0301
   PubMed Web of Science ®Google Scholar
• Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013; 23:249-62; PMID:23410977; https://doi.org/10.1016/j.ccr.2013.01.008
   PubMed Web of Science ®Google Scholar
• Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010; 16:4583-94; PMID:20702612; https://doi.org/10.1158/1078-0432.CCR-10-0733
   PubMed Web of Science ®Google Scholar
• Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011; 19:31-44; PMID:21215706; https://doi.org/10.1016/j.ccr.2010.11.009
   PubMed Web of Science ®Google Scholar
• Wang B, Xu D, Yu X, Ding T, Rao H, Zhan Y, Zheng L, Li L. Association of intra-tumoral infiltrating macrophages and regulatory T cells is an independent prognostic factor in gastric cancer after radical resection. Ann Surg Oncol 2011; 18:2585-93; PMID:21347781; https://doi.org/10.1245/s10434-011-1609-3
   PubMed Web of Science ®Google Scholar
• Di Caro G, Cortese N, Castino GF, Grizzi F, Gavazzi F, Ridolfi C, et al. Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut 2016; 65(10):1710-20; PMID:26156960; https://doi.org/10.1136/gutjnl-2015-309193
   PubMed Web of Science ®Google Scholar
• Galdiero MR, Bianchi P, Grizzi F, Di Caro G, Basso G, Ponzetta A, Bonavita E, Barbagallo M, Tartari S, Polentarutti N, et al. Occurrence and significance of tumor-associated neutrophils in patients with colorectal cancer. Int J Cancer 2016; 139:446-56; PMID:26939802; https://doi.org/10.1002/ijc.30076
   PubMed Web of Science ®Google Scholar
• Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S. Tumor associated macrophages and neutrophils in cancer. Immunobiology 2013; 218:1402-10; PMID:23891329; https://doi.org/10.1016/j.imbio.2013.06.003
   PubMed Web of Science ®Google Scholar
• Shen MX, Hu PP, Donskov F, Wang GH, Liu Q, Du JJ. Tumor-associated neutrophils as a new prognostic factor in cancer: A systematic review and meta-analysis. Plos One 2014; 6; 9(6); PMID:24906014; https://doi.org/10.1371/journal.pone.0098259
   PubMed Web of Science ®Google Scholar
• Ohnishi K, Komohara Y, Saito Y, Miyamoto Y, Watanabe M, Baba H, Takeya M. CD169-positive macrophages in regional lymph nodes are associated with a favorable prognosis in patients with colorectal carcinoma. Cancer science 2013; 104:1237-44; PMID:23734742; https://doi.org/10.1111/cas.12212
   PubMed Web of Science ®Google Scholar
• Cavnar MJ, Turcotte S, Katz SC, Kuk D, Gonen M, Shia J, Allen PJ, Balachandran VP, D'Angelica MI, Kingham TP, et al. Tumor-Associated Macrophage Infiltration in Colorectal Cancer Liver Metastases is Associated With Better Outcome. Ann Surg Oncol 2017; 24(7):1835-1842; PMID:28213791; https://doi.org/10.1245/s10434-017-5812-8
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; https://doi.org/10.1126/science.1129139
   PubMed Web of Science ®Google Scholar
• Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Eng J Med 2005; 353:2654-66; PMID:16371631; https://doi.org/10.1056/NEJMoa051424
   PubMed Web of Science ®Google Scholar
• Laoui D, Van Overmeire E, Di Conza G, Aldeni C, Keirsse J, Morias Y, Movahedi K, Houbracken I, Schouppe E, Elkrim Y, et al. Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res 2014; 74:24-30; PMID:24220244; https://doi.org/10.1158/0008-5472.CAN-13-1196
   PubMed Web of Science ®Google Scholar
• Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342:971-6; PMID:24264990; https://doi.org/10.1126/science.1240537
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer cell 2015; 28:690-714; PMID:26678337; https://doi.org/10.1016/j.ccell.2015.10.012
   PubMed Web of Science ®Google Scholar
• Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29:482-91; PMID:19881547; https://doi.org/10.1038/onc.2009.356
   PubMed Web of Science ®Google Scholar
• Nagasaki E, Takahara A, Koido S, Sagawa Y, Aiba K, Tajiri H, Yagita H, Homma S. Combined Treatment With Dendritic Cells and 5-fluorouracil Elicits Augmented NK Cell-mediated Antitumor Activity Through the Tumor Necrosis Factor-alpha Pathway. J Immunother 2010; 33:467-74; PMID:20463601; https://doi.org/10.1097/CJI.0b013e3181d36726
   PubMed Web of Science ®Google Scholar
• Malesci A, Laghi L, Bianchi P, Delconte G, Randolph A, Torri V, Carnaghi C, Doci R, Rosati R, Montorsi M, et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res 2007; 13:3831-9; PMID:17606714; https://doi.org/10.1158/1078-0432.CCR-07-0366
   PubMed Web of Science ®Google Scholar